Ashleigh O’Connell

1.0k total citations · 1 hit paper
19 papers, 790 citations indexed

About

Ashleigh O’Connell is a scholar working on Molecular Biology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Ashleigh O’Connell has authored 19 papers receiving a total of 790 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 12 papers in Hematology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Ashleigh O’Connell's work include Hedgehog Signaling Pathway Studies (14 papers), Acute Myeloid Leukemia Research (10 papers) and Tumors and Oncological Cases (7 papers). Ashleigh O’Connell is often cited by papers focused on Hedgehog Signaling Pathway Studies (14 papers), Acute Myeloid Leukemia Research (10 papers) and Tumors and Oncological Cases (7 papers). Ashleigh O’Connell collaborates with scholars based in United States, Germany and Spain. Ashleigh O’Connell's co-authors include Jörge E. Cortes, Geoffrey Chan, M. Naveed Shaik, Weidong Wendy, Mirjana Zeremski, Daniel A. Pollyea, Alexander Laird, Tadeusz Robak, Michael Heuser and Walter Fiedler and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Ashleigh O’Connell

19 papers receiving 775 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

2018 354 citations Jörge E. Cortes, Florian H. Heidel et al. Leukemia profile →

Peers

Countries citing papers authored by Ashleigh O’Connell

Since Specialization

Citations

This map shows the geographic impact of Ashleigh O’Connell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ashleigh O’Connell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ashleigh O’Connell more than expected).

Fields of papers citing papers by Ashleigh O’Connell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ashleigh O’Connell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ashleigh O’Connell. The network helps show where Ashleigh O’Connell may publish in the future.

Co-authorship network of co-authors of Ashleigh O’Connell

This figure shows the co-authorship network connecting the top 25 collaborators of Ashleigh O’Connell. A scholar is included among the top collaborators of Ashleigh O’Connell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ashleigh O’Connell. Ashleigh O’Connell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM). 2024 ·Journal of Clinical Oncology ·Alexander M. Lesokhin, (unknown), Jorge Acosta‐Reyes, Patrick Muller, Ashleigh O’Connell, (unknown), (unknown), (unknown)	3
2	Magnetismm-4: An Open Label, Phase 1B/2 Umbrella Study of Elranatamab in Combination with Other Anti-Cancer Treatments for Patients with Multiple Myeloma 2022 ·Blood ·Ola Landgren, Dickran Kazandjian, Ashleigh O’Connell, (unknown), Noopur Raje	10
3	Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial 2021 ·Annals of Hematology ·Michael Heuser, B. Douglas Smith, Walter Fiedler, Mikkael A. Sekeres, Pau Montesinos, Brian Leber, Akil Merchant, Cristina Papayannidis, Josè Antonio Pérez-Simón, (unknown), Thomas O’Brien, Weidong Wendy, Mirjana Zeremski, Ashleigh O’Connell, Geoffrey Chan, Jörge E. Cortes	36
4	Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy 2020 ·Journal of Hematology & Oncology ·Jörge E. Cortes, Florian H. Heidel, Walter Fiedler, Benjamin D. Smith, Tadeusz Robak, Pau Montesinos, Anna Candoni, Brian Leber, Mikkael A. Sekeres, Daniel A. Pollyea, (unknown), Weidong Wendy, Thomas O’Brien, Ashleigh O’Connell, Geoffrey Chan, Michael Heuser	29
5	Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up. 2020 ·Journal of Clinical Oncology ·Michael Heuser, Tadeusz Robak, Pau Montesinos, Brian Leber, Walter Fiedler, Daniel A. Pollyea, Andrew Brown, Ashleigh O’Connell, (unknown), Geoffrey Chan, Jörge E. Cortes	9
6	Effect of early blood counts on overall survival (OS) following glasdegib + LDAC in newly diagnosed AML: BRIGHT AML 1003 post hoc analysis. 2020 ·Journal of Clinical Oncology ·Eunice S. Wang, Michael Heuser, Mikkael A. Sekeres, Cristina Papayannidis, Anna Candoni, Akil Merchant, Andrew Brown, Ashleigh O’Connell, (unknown), Geoffrey Chan, Jörge E. Cortes	1
7	Low-Dose Cytarabine With or Without Glasdegib in Newly Diagnosed Patients with Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial 2019 ·Clinical Lymphoma Myeloma & Leukemia ·Cristina Papayannidis, B. Douglas Smith, Michael Heuser, Pau Montesinos, Mikkael A. Sekeres, Albert Oriol, Gary J. Schiller, Anna Candoni, Catriona Jamieson, (unknown), Weidong Wendy, Mirjana Zeremski, Ashleigh O’Connell, Geoffrey Chan, Jörge E. Cortes	4
8	Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: Long-term analysis of a phase 2 randomized trial. 2019 ·Journal of Clinical Oncology ·B. Douglas Smith, Cristina Papayannidis, Michael Heuser, Pau Montesinos, Mikkael A. Sekeres, Albert Oriol, Gary J. Schiller, Anna Candoni, Catriona Jamieson, (unknown), (unknown), Mirjana Zeremski, Ashleigh O’Connell, Geoffrey Chan, Jörge E. Cortes	6
9	Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia 2019 ·Blood ·Amer M. Zeidan, Michael W. Schuster, Jürgen Krauter, Johan Maertens, Emmanuel Gyan, Magalie Joris, Tobias Menne, Paresh Vyas, Weidong Wendy, Ashleigh O’Connell, Mirjana Zeremski, Arthur J. Kudla, Geoffrey Chan, Mikkael A. Sekeres	10
10	Glasdegib with LDAC in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) Unsuitable for Intensive Chemotherapy: Effects on Transfusions and Marrow Recovery vs LDAC Alone 2019 ·Clinical Lymphoma Myeloma & Leukemia ·Eunice S. Wang, Michael Heuser, Pau Montesinos, Mikkael A. Sekeres, Akil Merchant, (unknown), Olga Salamero, James McCloskey, (unknown), Weidong Wendy, Mirjana Zeremski, Ashleigh O’Connell, Geoffrey Chan, Jörge E. Cortes	1
11	PF272 GLASDEGIB WITH LDAC IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNSUITABLE FOR INTENSIVE CHEMOTHERAPY: EFFECTS ON TRANSFUSIONS AND MARROW RECOVERY VS LDAC ALONE 2019 ·HemaSphere ·(unknown), Michael Heuser, Pau Montesinos, Mikkael A. Sekeres, Akil Merchant, (unknown), Olga Salamero, James McCloskey, (unknown), (unknown), Mirjana Zeremski, Ashleigh O’Connell, Geoffrey Chan, Jörge E. Cortes	2
12	Clinical Benefit of Glasdegib Plus Low-Dose Cytarabine in Patients with De Novo and Secondary Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial 2019 ·Clinical Lymphoma Myeloma & Leukemia ·Michael Heuser, Walter Fiedler, Mikkael A. Sekeres, Pau Montesinos, Brian Leber, Akil Merchant, Cristina Papayannidis, Josè Antonio Pérez-Simón, (unknown), Weidong Wendy, Mirjana Zeremski, Ashleigh O’Connell, Geoffrey Chan, Jörge E. Cortes	5
13	PF292 LOW‐DOSE CYTARABINE WITH OR WITHOUT GLASDEGIB IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA: LONG‐TERM ANALYSIS OF A PHASE 2 RANDOMIZED TRIAL 2019 ·HemaSphere ·Cristina Papayannidis, B. Douglas Smith, Michael Heuser, Pau Montesinos, Mikkael A. Sekeres, Albert Oriol, Gary J. Schiller, Anna Candoni, Carol Jamieson, (unknown), (unknown), Mirjana Zeremski, Ashleigh O’Connell, Geoffrey Chan, Jörge E. Cortes	1
14	Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS 2018 ·Clinical Cancer Research ·Michael R. Savona, Daniel A. Pollyea, Wendy Stock, Vivian G. Oehler, Mark A. Schroeder, Jeffrey E. Lancet, James McCloskey, Hagop M. Kantarjian, Weidong Wendy, M. Naveed Shaik, Alexander Laird, Mirjana Zeremski, Ashleigh O’Connell, Geoffrey Chan, Jörge E. Cortes	86
15	Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome breakdown → 2018 ·Leukemia ·Jörge E. Cortes, Florian H. Heidel, Andrzej Hellmann, Walter Fiedler, B. Douglas Smith, Tadeusz Robak, Pau Montesinos, Daniel A. Pollyea, P. Desjardins, Oliver G. Ottmann, Weidong Wendy, M. Naveed Shaik, Alexander Laird, Mirjana Zeremski, Ashleigh O’Connell, Geoffrey Chan, Michael Heuser	354
16	Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results 2018 ·American Journal of Hematology ·Jörge E. Cortes, Benjamin D. Smith, Eunice S. Wang, Akil Merchant, Vivian G. Oehler, Martha Arellano, Daniel J. DeAngelo, Daniel A. Pollyea, Mikkael A. Sekeres, Tadeusz Robak, Weidong Wendy, Mirjana Zeremski, M. Naveed Shaik, Alexander Laird, Ashleigh O’Connell, Geoffrey Chan, Mark A. Schroeder	94
17	Glasdegib in Addition to Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Safety Analysis of Glasdegib 'On Target' Adverse Events 2018 ·Blood ·Jörge E. Cortes, Cristina Papayannidis, Catriona Jamieson, Gary J. Schiller, Anna Candoni, Brian Leber, Claudia D. Baldus, Josè Antonio Pérez-Simón, Weidong Wendy, Corrado Gallo Stampino, Ashleigh O’Connell, Mirjana Zeremski, Geoffrey Chan, Mikkael A. Sekeres	5
18	A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF-04449913) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome 2016 ·Blood ·Jörge E. Cortes, Florian H. Heidel, Michael Heuser, Walter Fiedler, B. Douglas Smith, Tadeusz Robak, (unknown), Weidong Wendy, M. Naveed Shaik, Mirjana Zeremski, Ashleigh O’Connell, Geoffrey Chan	37
19	Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study 2015 ·The Lancet Haematology ·Giovanni Martinelli, Vivian G. Oehler, Cristina Papayannidis, Rachel Courtney, M. Naveed Shaik, Xiaoxi Zhang, Ashleigh O’Connell, Karen R. McLachlan, Xianxian Zheng, Jerald P. Radich, Michele Baccarani, Hagop M. Kantarjian, Wendy J. Levin, Jörge E. Cortes, Catriona Jamieson	97

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact